Dr. Patrick Hanley, assistant research professor of pediatrics in the Center for Cancer and Immunology research at the Children’s Research Institute in Washington D.C. and director of the Good Manufacturing Practices cell therapy laboratory at Children’s National Health System, on the new developments in the design and manufacturing for T cell therapies. He discussed ways in which technology can help simplify the methodologies and bring consistency and scalability to cell manufacturing.
Georgia Tech Engineers created an organization to develop standards and production processes designed to mass produce life-saving cell-based therapeutics at affordable prices. Via AABME.
Gain access to free tools and resources from AABME, an initiative designed to stimulate biomedical innovation by bringing together and providing resources to the biomedical engineering community.
A new ultrasound technique that manipulates immune cells from outside the body could be the future of cancer care.
Researchers discover new molecular linker that orients targeting antibodies to help nucleic-acid filled particles reach target cells via AABME
Testing drugs against patients’ cancer cells—without subjecting patients to chemotherapy—could lead to better, faster treatment.
A new breakthrough in anti-aging research could lead to gene and stem cell therapies that turn back the hands of time.
Researchers at the University of Pittsburgh’s Center for Cellular and Molecular Engineering have developed a small bioreactor that grows constructs of bone and cartilage in a single chamber.
Regenerative medicine searches for ways to move into larger tests and commercial products.
A combined bioreactor and cell culture analyzer automatically monitors and adjusts growing conditions on 48 different cell cultures.
A new system may help solve the problem of shipping cells between laboratories and hospitals and clinics by developing an alternative to cryopreservation.
Engineering and manufacturing expertise could ease the shortage of viral vectors used for drug delivery in the booming gene therapy market.
In the wake of recent developments in the field of cell therapy, bioprinter vendors are seeking to market to more sophisticated researchers.
New technologies for engineering cells, monitoring cellular attributes and accelerating manufacturing lead to better and safer cell therapy products.
Scientists are now developing alternative strategies for producing new types of CAR-T treatments.